
Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.
Chronic Lymphocytic Leukemia with Steven Coutre, MD
Steven Coutre, MD, shares insights into his approach to frontline therapy for chronic lymphocytic leukemia